Hostname: page-component-8448b6f56d-wq2xx Total loading time: 0 Render date: 2024-04-23T19:55:44.669Z Has data issue: false hasContentIssue false
  • English
  • Français

Depression—An Analysis of a Follow-up Study

Published online by Cambridge University Press:  29 January 2018

A. Kessell  and
N. F. Holt
A. Kessell
Affiliation:
Dandenong Psychiatric Centre, Victoria, Australia
N. F. Holt
Affiliation:
Mental Health Research Institute, Royal Park, Victoria, Australia
Get access Rights & Permissions [Opens in a new window]

Extract

The year 1957 heralded a significant advance in the treatment of depressive states. It was then that Loomer et al. (1957), and Crane (1957), published their findings on the use of iproniazid, and Kuhn (1957), published his findings on the use of imipramine. Iproniazid was the first of a series of monoamine oxidase inhibitors which were rapidly developed and used in the treatment of depressive states. In the last few years, their use, especially in “endogenous” depression, has been eclipsed by the iminodibenzyl derivatives; first imipramine, then amitriptyline and later the demethylated derivatives, desipramine and nortriptyline. However, the later monoamine oxidase inhibitors are still widely used, especially in “reactive” depression and some neurotic states.

Type
Research Article
Information
The British Journal of Psychiatry , Volume 111 , Issue 481 , December 1965 , pp. 1143 - 1153
Copyright
Copyright © Royal College of Psychiatrists, 1965 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Abraham, H. C., Kanter, V. B., Rosen, I., and Standen, J. L. (1963). “A controlled clinical trial of imipramine (Tofranil) with outpatients.” Brit. J. Psychiat., 109, 286.CrossRefGoogle ScholarPubMed
Akimoto, H., Makakuki, M., Honda, Y., Takakahashi, Y., Toyoda, J., Sasaki, K., and Machiyama, Y. (1962). “Clinical evaluation of the effect of central stimulants, M.A.O. inhibitors and imipramine in the treatment of affective disorders”, in Third World Congress of Psychiatry Proceedings. McGill University Press.Google Scholar
Andersen, H., and Kristiansen, E. S. (1959). “Tofranil treatment of endogenous depressions.” Acta. psychiat. et neurol. scand., 34, 387.Google Scholar
Angst, J. (1961). “A clinical analysis of the effects of Tofranil in depression.” Psychopharmacologia, 2, 381.Google Scholar
Angst, J. (1963). “Comparison of the antidepressant properties of amitriptyline and imipramine.” Ibid., 4, 389.Google Scholar
Astrup, D., Fossum, A., and Holmbae, R. (1959). “A follow-up study of 270 patients with acute affective psychoses.” Acta psychiat. et neurol. scand., 34, Suppl. 34.Google ScholarPubMed
Ayd, F. J. (1961). “A critique of antidepressants.” Dis. New. Syst., 22, Suppl. 22.Google Scholar
Browne, M. W., Frieger, L. C., and Kazamias, N. G. (1963). “A clinical trial of amitriptyline in depressive states.” Brit. J. Psychiat., 109, 692.Google Scholar
Burt, C. G., Gordon, W. F., Holt, N. R., and Hordern, A. (1962). “Amitriptyline in depressive states: a controlled trial.” J. ment. Sci., 108, 711.Google Scholar
Busfield, B. L., Wechsler, H., and Barnum, W. J. (1962). “A physiological correlate of diagnosis and treatment outcome in depression”, in Third World Congress of Psychiatry Proceedings, ii, 1367. Montreal.Google Scholar
Clark, J. A., and Mallett, B. L. (1963). “A follow-up study of schizophrenia and depression in young adults.” Brit. J. Psychiat., 109, 491.CrossRefGoogle ScholarPubMed
Crane, G. E. (1957). “Iproniazid (Marsilid) Phosphate, a therapeutic agent for mental disorders and debilitating diseases.” Psychiat. Res. Reports, 8, 142.Google Scholar
Fink, M. (1959). “Electroencephalographic and behavioural effects of Tofranil.” Canad. Psychiat. Ass. J., 4, 166.Google Scholar
Fleminger, J. J., and Groden, B. M. (1962). “Clinical features of depression and the response to imipramine (Tofranil).” J. ment. Sci., 108, 101.Google Scholar
Freyhan, F. A. (1960). “The modern treatment of depressive disorders.” Amer. J. Psychiat., 117, 1057.Google Scholar
Friedman, C., De Mowbray, M. S. and Hamilton, V. (1961). “Imipramine (Tofranil) in depressive states.” Ibid., 197, 948.Google Scholar
Garmany, G. (1958). “Depressive states: their aetiology and treatment.” Brit. Med. J., ii, 341.Google Scholar
Goldner, R. D. (1962). “Control of minor criminal sexual compulsions with imipramine and amine oxidase regulators”, in Third World Congress of Psychiatry Proceedings. McGill University Press.Google Scholar
Hamilton, M. (1960). “A rating scale for depression.” J. Neurol. Neurosurg. and Psychiat., 23, 56.Google Scholar
Himwich, H. E., Morillo, A., and Steiner, W. G. (1962). “Drugs affecting rhinencephalic structures.” J. Neuropsychiat., 3, Suppl. 3.Google Scholar
Hobson, R. F. (1953). “Prognostic factors in electroconvulsive therapy.” J. Neurol. Neurosurg. and Psychiat., 16, 275.Google Scholar
Hoenig, J., and Visram, S. (1964). “Amitriptyline versus imipramine in depressive psychoses.” Brit. J. Psychiat., 110, 840.Google Scholar
Hordern, A., Holt, N. F., Burt, C. G., and Gorden, W. F. (1963). “Amitriptyline in depressive states.” Ibid., 109, 815.Google ScholarPubMed
Huston, P. E., and Locher, L. M. (1948). “Manic-depressive psychosis, course when treated and untreated with electro-shock.” Arch. Neurol. Psychiat., 60, 37.Google Scholar
Jarvie, H. F. (1954). “Prognosis of depression treated by electric convulsion therapy.” Brit. Med. J., i, 132.Google Scholar
Kalow, W. (1962). Pharmacogenetics. London.Google Scholar
Kaplan, S. M., Kravetz, R. S., and Ross, W. D. (1962). “The effects of imipramine in the depressive components of medical disorders”, in Third World Congress of Psychiatry Proceedings. McGill University Press.Google Scholar
Karagulla, S. (1950). “Evaluation of electric convulsive therapy as compared with conservative methods of treatment in depressive states.” J. ment. Sci., 66, 1060.Google Scholar
Kessell, A. (1964). “Classification and diagnosis in psychiatry.” Med. J. Aust., ii, 784.CrossRefGoogle Scholar
Kiloh, L. G., Ball, J. R. B., and Garside, R. F. (1962). “Prognostic factors in the treatment of depressive states with imipramine.” Brit. Med. J., i, 1225.Google Scholar
Kiloh, L. G., Ball, J. R. B., and Garside, R. F. (1963). “The independence of neurotic and endogenous depression.” Brit. J. Psychiat., 109, 451.Google Scholar
Kline, N. S. (1961). “Depression: diagnosis and treatment.” Med. Clinics. of N. America, 45, 1041.Google Scholar
Kreitman, N., Sainsbury, P., Morrissey, J., Towers, J., and Scrivener, J. (1961). “The reliability of psychiatric assessment: an analysis.” J. ment. Sci., 107, 887.Google Scholar
Kuhn, R. (1957). “Über die Behandlung depressiver Zustände mit einem iminodibenzylderivat (G22355).” Schweiz. med. Wochenschr., 87, 1135.Google Scholar
Lewis, A. J. (1934). “Melancholia: a clinical survey of depressive states.” J. ment. Sci., 80, 277.Google Scholar
Leyberg, J. I., and Denmark, J. C. (1959). “The treatment of depressive states with imipramine hydrochloride (Tofranil).” Ibid., 105, 1123.Google ScholarPubMed
Loonier, H. P., Saunders, J. C., and Kline, N. S. (1957). “A clinical and pharmacodynamic evaluation of iproniazid as a psychic energiser.” Psychiat. Res. Reports, 8, 129.Google Scholar
Mapother, E. (1926). “Manic depressive psychosis.” Brit. med. J., ii, 872.Google Scholar
Oltman, J. E., and Friedman, S. (1962). “Comparison of temporal factors in depressive psychoses treated by E. C. T. and antidepressant drugs.” Amer. J. Psychiat., 119, 579.Google Scholar
Pare, C. M. B., Rees, L., and Sainsbury, M. J. (1962). “Differentiation of two genetically specific types of depression by response to antidepressants.” Lancet, ii, 1340.Google Scholar
Polonio, P. (1961). “Anti-depressive drugs in the treatment of depression.” Dis. New. Syst., 22, 449.Google Scholar
Rathbun, R. C., and Slater, I. H. (1963). “Amitriptyline and nortriptyline as antagonists of central and peripheral cholinergic activation.” Psychopharmacologia, 4, 114.Google Scholar
Roberts, J. M. (1959). “Prognostic factors in the electro-shock treatment of depressive states.” J. ment. Sci., 105, 693.Google Scholar
Robin, A. A., and Langley, G. E. (1964). “A controlled trial of imipramine.” Brit. J. Psychiat., 110, 419.Google Scholar
Rose, J. T. (1963). “Reactive and endogenous depressions —response to E.C.T.” Ibid., 109, 213.Google Scholar
Sandifer, M. G., Wilson, I. C., and Gambill, J. M. (1965). “The influence of case selection and dosage in an antidepressant drug trial.” Ibid., 111, 142.Google Scholar
Sargant, W. (1961). “The treatment of anxiety states and atypical depressions by the monoamine oxidase inhibitor drugs.” J. Neuropsychiat., 3, 96.Google Scholar
Schou, M. (1963). “Normothymotics, ‘Mood normalizers'.” Brit. J. Psychiat., 109, 803.Google Scholar
Sigg, E. B. (1959). “Pharmacological studies with Tofranil.” Canad. Psychiat. Ass. J., 4, 75.Google Scholar
Skarbeck, A. (1963). “Trial of amitriptyline in chronic depression.” Dis. New. Syst., 24, 115.Google Scholar
Thomas, D. L. C. (1954). “Prognoses of depression with electrical treatment.” Brit. Med. J., ii, 950.Google Scholar
Vernier, V. G. (1961). “The pharmacology of antidepressant agents.” Dis. New. Syst., 22, 7.Google Scholar
West, E. D., and Dally, P. J. (1959). “Effects of iproniazid in depressive syndromes.” Brit. Med. J., i, 1491.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.